Comparison between different doses of gonadotropin-releasing hormone agonist used in short stimulation protocol in infertile women undergoing IVF

Hormonal responses and clinical outcome following three doses of gonadotropin-releasing hormone agonist used in short stimulation protocol in infertile patients undergoing in vitro fertilization cycles

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12613000384752

Enrollment

Registered

2013-04-10

Start date

2012-01-01

Completion date

2013-06-01

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Gonadotropin releasing hormone agonist (GnRH-a) is used routinely in controlled ovarian stimulation for assisted reproduction either in its short (flare-up) or long protocol. The routine daily dose of the different agonists was introduced by trials and is not uniformly established. The objective of this prospective randomized controlled study was to characterize the daily changes in the levels of luteinizing hormone (LH) and estradiol (E2) and to compare the intracytoplasmic sperm injection (ICSI) outcome with 3 different doses of the GnRH-a used in a short protocol for normal ovulatory females. Patientswill be randomly assigned to three groups; group A (N=34), group B (N=34) and group C (N=23). All the patients will start treatment with urinary gonadotropins, 2 ampoules per day and GnRH-a (Triptorelin) on the first day of the menstrual period and continued till the day of human chorionic gonadotropins (hCG) administration. The daily dose of Triptorelin will be 0.1 mg, 50 ug, and 25 ug in groups A, B and C respectively.

Interventions

Ovulatory patients undergoing in vitro fertilization cycles will start treatment with intramuscular injection of urinary gonadotropins, 2 ampoules (150 IU) per day and subcutaneous injections of GnRH-a (Triptorelin) on the first day of the menstrual period and continued till the day of human chorionic gonadotropins (hCG) administration. We administered human chorionic gonadotropin (hCG) when at least three follicles of 16 mm or more in diameter and adequate estradiol plasma concentrations were

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 42 Years

Healthy volunteers

Inclusion criteria

Infertile patients undergoing in vitrofertilization cycles,

Exclusion criteria

Patients with ovarian failure

Outcome results